Biogen Reports Q2 Revenue Growth Driven by Strong Performance of Growth Portfolio
Biogen Inc. (NASDAQ:BIIB) reported second-quarter revenue of $2.7 billion for the period ending June 30, 2026, representing a year-over-year increase of 3%. The growth was primarily driven by its high-performing portfolio and contributions from newly acquired Apellis products. Revenue from Biogen's core pharmaceutical business rose 4% to $1.8 billion, while the company’s growth portfolio generated over $1 billion in revenue—a 24% year-over-year increase. Key product performance varied: SPINRAZA saw strong adoption of its high-dose regimen and exceeded initial launch expectations; LEQEMBI continued growing across key markets including the U.S., Japan, and China. SYFOVRE and EMPAVELI contributed $128 million in revenue since their acquisition on May 14. Biogen also raised its full-year revenue outlook to mid-single-digit growth with a non-GAAP EPS guidance of $12–$13. The company expects at least $250 million in annualized cost synergies from the Apellis integration by the end of 2027 and remains focused on expanding access for its therapies, including new launches like ZURZUVAE in Germany.
Topics: apellis_acquisition biogen pharmaceuticals revenue_growth